Literature DB >> 27538967

[Effects of modified inclusion criteria and negative reporting about PSA screening on the number of potentially recruitable patients for the PREFERE study].

J Mathes1, M Burger2, J E Gschwend3, O W Hakenberg4, S Krege5, J Lehmann6, K Miller7, J Roigas8, S Roth9, T Kälble10.   

Abstract

BACKGROUND: The PREFERE study is currently below expectations. The objective of this study was to investigate the effect of the modification of the inclusion criteria in 2015 on the number of recruitable patients with localized prostate cancer. Furthermore we analyzed whether fewer cases of low-risk prostate cancer were detected in 2014 than in 2010. PATIENTS AND METHODS: Prostate biopsies of 2136 patients (9 hospitals) of the years 2010 and 2014 were retrospectively reviewed, regarding the eligibility for participation in the PREFERE study.
RESULTS: According to PREFERE criteria version 3.2, 16.8 % (in 2010) and 16.7 % (in 2014) of the patients fulfilled the inclusion criteria for the study, whereas 41.9 % (in 2010) and 30.1 % (in 2014) of the patients met the criteria in version 5.0.
CONCLUSIONS: Our results indicate that the modified inclusion criteria result in an increase in the number of recruitable patients for the PREFERE study. Furthermore, there were 11.8 % fewer cases of potentially recruitable patients in 2014 than in 2010 by use of version 5.0. This is a possible indication for an altered use of prostate biopsy.

Entities:  

Keywords:  Inclusion criteria; Low-risk prostate cancer; PREFERE study; Prostate biopsy

Mesh:

Substances:

Year:  2016        PMID: 27538967     DOI: 10.1007/s00120-016-0211-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  18 in total

1.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

2.  Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting.

Authors:  Lars Holmberg; Anna Bill-Axelson; Gunnar Steineck; Hans Garmo; Juni Palmgren; Eva Johansson; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

3.  103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice.

Authors:  Jerrold Sharkey; Alan Cantor; Zucel Solc; William Huff; Stanley D Chovnick; Raymond J Behar; Ramon Perez; Juan Otheguy; Richard Rabinowitz
Journal:  Brachytherapy       Date:  2005       Impact factor: 2.362

4.  Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Authors:  Julia H Hayes; Daniel A Ollendorf; Steven D Pearson; Michael J Barry; Philip W Kantoff; Susan T Stewart; Vibha Bhatnagar; Christopher J Sweeney; James E Stahl; Pamela M McMahon
Journal:  JAMA       Date:  2010-12-01       Impact factor: 56.272

5.  Stage migration in clinically localized prostate cancer.

Authors:  J Noldus; M Graefen; A Haese; R P Henke; P Hammerer; H Huland
Journal:  Eur Urol       Date:  2000-07       Impact factor: 20.096

6.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

7.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

8.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Authors:  Laurence Klotz; Liying Zhang; Adam Lam; Robert Nam; Alexandre Mamedov; Andrew Loblaw
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

Review 9.  Prostate cancer management: (1) an update on localised disease.

Authors:  S R J Bott; A J Birtle; C J Taylor; R S Kirby
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

10.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Authors:  Patrick A Kupelian; Louis Potters; Deepak Khuntia; Jay P Ciezki; Chandana A Reddy; Alwyn M Reuther; Thomas P Carlson; Eric A Klein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-01-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.